Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma

Leukemia and Lymphoma

Volumn 54, Issue 9, 2013, Pages 1898-1907

  Jardin, Fabrice ^a   Delfau Larue, Marie Hélène ^b   Molina, Thierry Jo ^c   Copie Bergman, Christiane ^b   Brière, Josette ^c   Petrella, Tony ^d   Canioni, Danielle ^e   Fabiani, Bettina ^h   Jais, Jean Philippe ^f   Figeac, Martin ⁱ   Leroy, Karen ^b   Mareschal, Sylvain ^a   Salles, Gilles André ^j   Coiffier, Bertrand ^j   Delarue, Richard ^g   Peyrade, Frédéric ^k   Bosly, André ^l   André, Marc ^l   Ketterer, Nicolas ^m   Haioun, Corinne ^b   Tilly, Hervé ^a   more..

^a CENTRE HENRI BECQUEREL   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d DIJON UNIVERSITY HOSPITAL   (France)

^e AP HP Hô Pital Saint Louis   (France)

^f Laboratoire de Pathologie ^*  (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h HÔPITAL SAINT ANTOINE   (France)

ⁱ UNIV LILLE   (France)

^j UNIVERSITÉ LYON 1   (France)

^k Lacassagne Center   (France)

^l UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^m Children's Hospital Lausanne   (Switzerland)

more..

Author keywords

Chemotherapeutic approaches; Lymphoma and Hodgkin disease; Prognostication

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL SELECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN LIGHT CHAINS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; VINCRISTINE;

EID: 84883018866     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.767456     Document Type: Article

References (33)

1. MJ, Cerhan JR, Katzmann JA, et al. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood 2011;118:2821-2826.
2. Drake MT, Maurer MJ, Link BK, et al. Vitamin D insufficiency and prognosis in non-Hodgkin ' s lymphoma. J Clin Oncol 2010;28:4191-4198.
3. Last KW, Cornelius V, Delves T, et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-Hodgkin ' s lymphoma. J Clin Oncol 2003;21:2335-2341.
4. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diff use large B-cell lymphoma. Br J Haematol 2008;141:672-675.
5. Lech-Maranda E, Bienvenu J, Michallet AS, et al. Elevated IL-10 plasma levels correlate with poor prognosis in diff use large B-cell lymphoma. Eur Cytokine Netw 2006;17:60-66.
6. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diff use large B-cell lymphoma: Clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 2005;23:2797-2804.
7. Niitsu N, Okamoto M, Okabe-Kado J, et al. Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin ' s lymphoma. Leukemia 2001;15:832-839.
8. Goto N, Tsurumi H, Kasahara S, et al. Serum interleukin-18 level is associated with the outcome of patients with diff use large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol 2011;87:217-227.
9. Bono P, Teerenhovi L, Joensuu H. Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 2003;97:2767-2775.
10. Giachelia M, Voso MT, Tisi MC, et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-kappaB1 gene and are associated with outcome following rituximab-combined chemotherapy in diff use large B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012;53:411-416.
11. Wang L, Liu P, Chen X, et al. Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diff use large B-cell lymphoma treated with rituximab-based immunochemotherapy. Med Oncol 2012;29:2153-2158.
12. Martin W, Abraham R, Shanafelt T, et al. Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 2007;149:231-235.
13. Charafeddine KM, Jabbour MN, Kadi RH, et al. Extended use of serum free light chain as a biomarker in lymphoproliferative disorders :A comprehensive review. Am J Clin Pathol 2012;137:890-897.
14. Maurer MJ, Micallef IN, Cerhan JR, et al. Elevated serum free light chains are associated wiThevent-free and overall survival in two independent cohorts of patients with diff use large B-cell lymphoma. J Clin Oncol 2011;29:1620-1626.
15. Furtado M, Shah N, Levoguer A, Harding S, Rule S. Abnormal serum free light chain ratio predicts poor overall survival in mantle cell lymphoma. Br J Haematol 2013;160:63-69.
16. Thompson CA, Maurer MJ, Cerhan JR, et al. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol 2011;86:998-1000.
17. Bradwell AR, Harding SJ, Fourrier NJ, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009;55:1646-1655.
18. Leleu X, Koulieris E, Maltezas D, et al. Novel M-component based biomarkers in Waldenstrom ' s macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:164-167.
19. Avet-Loiseau H, Harousseau J, Moreau P, et al. Heavy/light chain specific immunoglobulin ratios at presentation are prognostic for progression free survival in the IFM 2005-01 myeloma trial. Blood 2009;114:Abstract 1818.
20. Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diff use large B-cell lymphoma (LNH03-2B):An openlabel randomised phase 3 trial. Lancet 2011;378:1858-1867.
21. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diff use large B-cell lymphoma :A multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460-468.
22. Fitoussi O, Belhadj K, Mounier N, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diff use large B-cell lymphoma for GELA. Haematologica 2011;96:1136-1143.
23. Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diff use large B-cell lymphoma: Results of the interim analysis of the LNH03-6B GELA study. Blood 2009;114:Abstract 406.
24. Jais JP, Haioun C, Molina TJ, et al. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diff use large B-cell lymphoma treated with CHOP and rituximab. Leukemia 2008;22:1917-1924.
25. Wright G, Tan B, Rosenwald A, et al. Agene expression-based method to diagnose clinically distinct subgroups of diff use large B cell lymphoma. Proc Natl Acad Sci USA 2003;100:9991-9996.
26. Hutchison CA, Cockwell P, Harding S, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes:An early marker of diabetic kidney disease? Expert Opin Ther Targets 2008;12:667-676.
27. Brunello A, Kapoor R, Extermann M. Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity. Am J Clin Oncol 2011;34:292-296.
28. Zimmermann H, Oschlies I, Fink S, et al. Plasmablastic posttransplant lymphoma: Cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder Registry. Transplantation 2012;93:543-550.
29. Shin HJ, Chung JS, Song MK, et al. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diff use large B-cell lymphoma. Cancer Chemother Pharmacol 2012;69:1165-1172.
30. Ruminy P, Etancelin P, Couronne L, et al. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diff use large B-cell lymphoma. Leukemia 2011;25:681-688.
31. Schroers R, Baraniskin A, Heute C, et al. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur J Haematol 2010;85:236-242.
32. Klapper W, Kreuz M, Kohler CW, et al. Patient age at diagnosis is associated with the molecular characteristics of diff use large B-cell lymphoma. Blood 2012;119:1882-1887.
33. Mareschal S, Lanic H, Ruminy P, et al. The proportion of activated B-cell like subtype among de novo diff use large B-cell lymphoma increases with age. Haematologica 2011;96:1888-1890.